Prophylactic granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials

Lillian Sung, Paul C. Nathan, Beverly Lange, Joseph Beyene, George R. Buchanan

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Purpose: To determine whether prophylactic hematopoietic colony-stimulating factors (CSFs) used in children with cancer reduce the rate of febrile neutropenia, hospitalization duration, documented infection rate, parenteral antibiotic duration, amphotericin B use, or infection-related mortality. Methods: We included studies in this meta-analysis if their populations consisted of children, if there was randomization between CSFs and placebo or no therapy, if CSFs were administered prophylactically (before neutropenia or febrile neutropenia), and if chemotherapy treatments preceding CSFs and placebo or no therapy were identical. From 971 reviewed study articles, 16 were included. Results: The mean rate of febrile neutropenia in the control arms was 57% (range, 39% to 100%). Using a random effects model, CSFs were associated with a reduction in febrile neutropenia, with a rate ratio of 0.80 (95% CI, 0.67 to 0.95; P = .01), and a decrease in hospitalization length, with a weighted mean difference of -1.9 days (95% CI, -2.7 to -1.1 days; P < .00001). CSF use was also associated with reduction in documented infections (rate ratio, 0.78; 95% CI, 0.62 to 0.97; P = .02) and reduction in amphotericin B use (rate ratio, 0.50; 95% CI, 0.28 to 0.87; P = .02). There was no difference in duration of parenteral antibiotic therapy (weighted mean difference, -4.3; 95% CI, -10.6 to 2.0 days; P = .2) or infection-related mortality (rate ratio, 1.02; 95% CI, 0.34 to 3.06; P = .97). Conclusion: CSFs were associated with a 20% reduction in febrile neutropenia and shorter duration of hospitalization; however, CSFs did not reduce infection-related mortality.

Original languageEnglish (US)
Pages (from-to)3350-3356
Number of pages7
JournalJournal of Clinical Oncology
Volume22
Issue number16
DOIs
StatePublished - 2004

Fingerprint

Colony-Stimulating Factors
Febrile Neutropenia
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Meta-Analysis
Randomized Controlled Trials
Drug Therapy
Neoplasms
Infection
Hospitalization
Amphotericin B
Mortality
Placebos
Anti-Bacterial Agents
Therapeutics
Random Allocation
Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{029e9f6cf9f2476496af6d6ac99f1f34,
title = "Prophylactic granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials",
abstract = "Purpose: To determine whether prophylactic hematopoietic colony-stimulating factors (CSFs) used in children with cancer reduce the rate of febrile neutropenia, hospitalization duration, documented infection rate, parenteral antibiotic duration, amphotericin B use, or infection-related mortality. Methods: We included studies in this meta-analysis if their populations consisted of children, if there was randomization between CSFs and placebo or no therapy, if CSFs were administered prophylactically (before neutropenia or febrile neutropenia), and if chemotherapy treatments preceding CSFs and placebo or no therapy were identical. From 971 reviewed study articles, 16 were included. Results: The mean rate of febrile neutropenia in the control arms was 57{\%} (range, 39{\%} to 100{\%}). Using a random effects model, CSFs were associated with a reduction in febrile neutropenia, with a rate ratio of 0.80 (95{\%} CI, 0.67 to 0.95; P = .01), and a decrease in hospitalization length, with a weighted mean difference of -1.9 days (95{\%} CI, -2.7 to -1.1 days; P < .00001). CSF use was also associated with reduction in documented infections (rate ratio, 0.78; 95{\%} CI, 0.62 to 0.97; P = .02) and reduction in amphotericin B use (rate ratio, 0.50; 95{\%} CI, 0.28 to 0.87; P = .02). There was no difference in duration of parenteral antibiotic therapy (weighted mean difference, -4.3; 95{\%} CI, -10.6 to 2.0 days; P = .2) or infection-related mortality (rate ratio, 1.02; 95{\%} CI, 0.34 to 3.06; P = .97). Conclusion: CSFs were associated with a 20{\%} reduction in febrile neutropenia and shorter duration of hospitalization; however, CSFs did not reduce infection-related mortality.",
author = "Lillian Sung and Nathan, {Paul C.} and Beverly Lange and Joseph Beyene and Buchanan, {George R.}",
year = "2004",
doi = "10.1200/JCO.2004.09.106",
language = "English (US)",
volume = "22",
pages = "3350--3356",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Prophylactic granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer

T2 - A meta-analysis of randomized controlled trials

AU - Sung, Lillian

AU - Nathan, Paul C.

AU - Lange, Beverly

AU - Beyene, Joseph

AU - Buchanan, George R.

PY - 2004

Y1 - 2004

N2 - Purpose: To determine whether prophylactic hematopoietic colony-stimulating factors (CSFs) used in children with cancer reduce the rate of febrile neutropenia, hospitalization duration, documented infection rate, parenteral antibiotic duration, amphotericin B use, or infection-related mortality. Methods: We included studies in this meta-analysis if their populations consisted of children, if there was randomization between CSFs and placebo or no therapy, if CSFs were administered prophylactically (before neutropenia or febrile neutropenia), and if chemotherapy treatments preceding CSFs and placebo or no therapy were identical. From 971 reviewed study articles, 16 were included. Results: The mean rate of febrile neutropenia in the control arms was 57% (range, 39% to 100%). Using a random effects model, CSFs were associated with a reduction in febrile neutropenia, with a rate ratio of 0.80 (95% CI, 0.67 to 0.95; P = .01), and a decrease in hospitalization length, with a weighted mean difference of -1.9 days (95% CI, -2.7 to -1.1 days; P < .00001). CSF use was also associated with reduction in documented infections (rate ratio, 0.78; 95% CI, 0.62 to 0.97; P = .02) and reduction in amphotericin B use (rate ratio, 0.50; 95% CI, 0.28 to 0.87; P = .02). There was no difference in duration of parenteral antibiotic therapy (weighted mean difference, -4.3; 95% CI, -10.6 to 2.0 days; P = .2) or infection-related mortality (rate ratio, 1.02; 95% CI, 0.34 to 3.06; P = .97). Conclusion: CSFs were associated with a 20% reduction in febrile neutropenia and shorter duration of hospitalization; however, CSFs did not reduce infection-related mortality.

AB - Purpose: To determine whether prophylactic hematopoietic colony-stimulating factors (CSFs) used in children with cancer reduce the rate of febrile neutropenia, hospitalization duration, documented infection rate, parenteral antibiotic duration, amphotericin B use, or infection-related mortality. Methods: We included studies in this meta-analysis if their populations consisted of children, if there was randomization between CSFs and placebo or no therapy, if CSFs were administered prophylactically (before neutropenia or febrile neutropenia), and if chemotherapy treatments preceding CSFs and placebo or no therapy were identical. From 971 reviewed study articles, 16 were included. Results: The mean rate of febrile neutropenia in the control arms was 57% (range, 39% to 100%). Using a random effects model, CSFs were associated with a reduction in febrile neutropenia, with a rate ratio of 0.80 (95% CI, 0.67 to 0.95; P = .01), and a decrease in hospitalization length, with a weighted mean difference of -1.9 days (95% CI, -2.7 to -1.1 days; P < .00001). CSF use was also associated with reduction in documented infections (rate ratio, 0.78; 95% CI, 0.62 to 0.97; P = .02) and reduction in amphotericin B use (rate ratio, 0.50; 95% CI, 0.28 to 0.87; P = .02). There was no difference in duration of parenteral antibiotic therapy (weighted mean difference, -4.3; 95% CI, -10.6 to 2.0 days; P = .2) or infection-related mortality (rate ratio, 1.02; 95% CI, 0.34 to 3.06; P = .97). Conclusion: CSFs were associated with a 20% reduction in febrile neutropenia and shorter duration of hospitalization; however, CSFs did not reduce infection-related mortality.

UR - http://www.scopus.com/inward/record.url?scp=4344638243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344638243&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.09.106

DO - 10.1200/JCO.2004.09.106

M3 - Article

C2 - 15310780

AN - SCOPUS:4344638243

VL - 22

SP - 3350

EP - 3356

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -